LOGIN  |  REGISTER
Astria Therapeutics

EQT completes public offering of common stock of Waystar

September 12, 2025 | Last Trade: US$37.06 2.56 -6.46
  • The offering resulted in aggregate proceeds of c. USD $705.8 million, of which EQT received c. USD 304.5 million

NEW YORK, Sept. 12, 2025 /PRNewswire/ -- An affiliate of the fund known as EQT VIII ("EQT") is pleased to announce the completion of an underwritten public offering (the "Offering") of c. 18.0 million shares of common stock of Waystar Holding Corp. (NASDAQ: WAY) (the "Company") ("Shares"), for aggregate proceeds of c. USD 705.8 million to all the selling stockholders.  As part of the Offering, EQT sold c. 7.8 million Shares (and now holds c. 24.9 million Shares) and received proceeds of c. USD 304.5 million. The remaining Shares sold in the Offering were sold by other stockholders of the Company. J.P. Morgan Securities LLC acted as underwriter of the Offering, which was completed on September 12, 2025. The Company did not sell any Shares in the Offering and did not receive any proceeds from the sale of the Shares sold by EQT and the other stockholders.

Contact

EQT Press Office, This email address is being protected from spambots. You need JavaScript enabled to view it. 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eqt/r/eqt-completes-public-offering-of-common-stock-of-waystar-holding-corp-,c4233996

The following files are available for download:

https://mb.cision.com/Main/87/4233996/3666139.pdf     

Press Release, EQT VIII, Waystar, 120925

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page